Search Results - "Huppertz, E"

Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001 by Köster, I, Huppertz, E, Hauner, H, Schubert, I

“…To identify direct health care costs of patients with diabetes in Germany in 2010, with focus on costs of treating hyperglycaemia and costs caused by diabetes…”
Get more information

Direct costs of diabetes mellitus in Germany - CoDiM 2000-2007 by Köster, I, Huppertz, E, Hauner, H, Schubert, I

“…The prevalence of treated diabetes in Germany and direct health care costs of individuals with diabetes were analysed for the 8-year period from 2000 to 2007,…”
Get more information

Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled - results of the DETECT study by Huppertz, E, Pieper, L, Klotsche, J, Stridde, E, Pittrow, D, Böhler, S, Lehnert, H

“…The quality of glycaemic control of patients with T1D and T2D can be assessed with HbA (1c) levels. We aimed to assess the quality of glycaemic control and the…”
Get more information

Methods of health economic evaluation for health services research by Icks, A, Chernyak, N, Bestehorn, K, Brüggenjürgen, B, Bruns, J, Damm, O, Dintsios, C-M, Dreinhöfer, K, Gandjour, A, Gerber, A, Greiner, W, Hermanek, P, Hessel, F, Heymann, R, Huppertz, E, Jacke, C, Kächele, H, Kilian, R, Klingenberger, D, Kolominsky-Rabas, P, Krämer, H, Krauth, C, Lüngen, M, Neumann, T, Porzsolt, F, Prenzler, A, Pueschner, F, Riedel, R, Rüther, A, Salize, H J, Scharnetzky, E, Schwerd, W, Selbmann, H-K, Siebert, H, Stengel, D, Stock, S, Völler, H, Wasem, J, Schrappe, M

“…On August 30, 2010, the German Network for Health Services Research [Deutsches Netzwerk Versorgungsforschung e. V. (DNVF e. V.)] approved the Memorandum III…”
Get more information

Prescription of insulin glargine in primary care practices in Germany by Rathmann, W, Haastert, B, Riebel, P, Schroeder-Bernhardi, D, Kostev, K, Huppertz, E, Giani, G

“…New classes of antidiabetic medications have been introduced, but details of their use are not well known. The aim was to assess prescription patterns and…”
Get more information

Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model" by Maxion-Bergemann, S, Huppertz, E, Jacobs, L D, Müller, E, Walleser, S

“…The purpose of this study was to compare the effect of insulin glargine (glargine) and NPH insulin (NPH) on long-term outcomes in type 2 diabetes patients…”
Get full text

Health-economic comparison of three recommended drugs for the treatment of osteoporosis by Brecht, J G, Kruse, H P, Möhrke, W, Oestreich, A, Huppertz, E

“…Osteoporosis is a large and growing disease with significant health consequences. Based on an evaluation of clinical evidence, the German osteology umbrella…”
Get more information

Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany by Schädlich, P K, Zeidler, H, Zink, A, Gromnica-Ihle, E, Schneider, M, Straub, C, Brecht, J G, Huppertz, E

“…Since November 1999, leflunomide (LEF), an innovative disease-modifying antirheumatic drug (DMARD), is available in Germany for treatment of rheumatoid…”
Get full text

Pharmacoeconomic analysis of osteoporosis treatment with risedronate by Brecht, J G, Kruse, H P, Felsenberg, D, Möhrke, W, Oestreich, A, Huppertz, E

“…Hip fracture is an important and costly problem. Therapy with the bisphosphonate risedronate effectively prevents hip and other fractures among women with…”
Get more information

DB2 COMPARING BRITISH AND GERMAN DIABETES GUIDANCE WITH RESPECT TO LONGTERM OUTCOMES AND ASSOCIATED COSTS: RESULTS FROMTHE EAGLE DIABETES SIMULATION MODEL by Mueller, E, Huppertz, E, Stridde, E

Get full text

PDB1 BETTER HBA1C CONTROL WITH BOT VERSUS CT AVOIDS LONG-TERM MICRO-VASCULAR COMPLICATIONS IN PATIENTS WITH TYPE-2-DIABETES: MODEL SIMULATIONS WITH THE DMM by Walzer, S, Huppertz, E, Mueller, E, Janka, HU

Get full text

PCN59 ECONOMIC BURDEN OF TREATING VIN AND VAIN 2/3 IN GERMANY by Schulz-Holstege, O, Hampl, M, Huppertz, E, Schmitter, S, Bönte, M, Kok, P

Get full text

PDB48 KNOWLEDGE ABOUT INSULIN AND WILLINGNESS TO USE IT INFLUENCE GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ONLY TREATED WITH ORAL ANTIDIABETIC DRUGS—A GERMAN SURVEY by Stridde, E, Göke, B, Huppertz, E, Weitkunat, R, Crispin, A

Get full text

PDB32 ECONOMIC EVALUATION OF THE LAPTOP-STUDY RESULTS by Högy, B, Janka, HU, Huppertz, E

Get full text

PDB32 LONG-TERM DIABETES COMPLICATIONS: INFLUENCE OF DELAY IN STARTING INTENSIFIED THERAPY AND OF PATIENT RATES TREATED TO TARGET A1C.ANALYSES WITH THE DIABETES MELLITUS MODEL (DMM) by Bergemann, R, Huppertz, E, Mueller, E, Maxion-Bergemann, S

Get full text

PCV37 ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY by Schadlich, PK, Lehmacher, W, Huppertz, E, Grewe, R, Brecht, JG

Get full text

Cost effectiveness of ramipril in patients at high risk for cardiovascular events: Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for germany from the statutory health Insurance perspective by SCHÄDLICH, Peter K, BRECHT, Josef Georg, RANGOONWALA, Badrudin, HUPPERTZ, Eduard

“…In the HOPE (Heart Outcomes Prevention Evaluation) trial, ramipril (compared with placebo) significantly reduced cardiovascular death and all-cause mortality…”
Get full text

PIN16 ECONOMIC BURDEN AND FACTORS INFLUENCING COSTS IN GERMAN PATIENTS HOSPITALISED FOR COMMUNITYACQUIRED PNEUMONIA (CAP) by Decker-Burgard, S, Ehrnsperger, M, Eichmann, FRW, Huppertz, E, Kreyenberg, K, Reitberger, U, Roscher, K, Spannheimer, A

Get full text

PDB1 IMPROVED GLYCAEMIC CONTROL AND LESS HYPOGLYCAEMIA WITH INSULIN GLARGINE COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES LEADS TO FEWER LONG-TERM COMPLICATIONS—RESULTS OF THE DIABETES MELLITUS SIMULATION MODEL by Maxion-Bergemann, S, Müller, E, Bergemann, R, Walleser, S, Huppertz, E

Get full text

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany. I. Selected DMARDs and patient-related costs by SCHÄDLICH, Peter K, ZEIDLER, Henning, ZINK, Angela, GROMNICA-IHLE, Erika, SCHNEIDER, Matthias, STRAUB, Christoph, BRECHT, Josef G, HUPPERTZ, Eduard

“…To quantify direct costs of medication and cost of illness (according to functional capacity) for patients with rheumatoid arthritis (RA) in Germany, allowing…”
Get full text